Education
About Us
Working with TipRanks
Follow Us
Pharming Group Nv (PHAR)
:PHAR
PHAR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.31 - $17.08
Previous CloseN/A
Volume181.00
Average Volume (3M)13.75K
Market Cap
$1.05B
Enterprise Value$744.24M
Total Cash (Recent Filing)$128.73M
Total Debt (Recent Filing)$128.33M
Price to Earnings (P/E)―
Beta0.50
Next Earnings
Nov 06, 2025EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding68,514,760
10 Day Avg. Volume14,689
30 Day Avg. Volume13,751
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.71
Enterprise Value/Revenue2.18
Enterprise Value/Gross Profit2.44
Enterprise Value/Ebitda24.47
Forecast
1Y Price Target
$39.00Price Target Upside153.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Financial PerformancePharming announced 2Q25 financial results, posting EPS of $0.006 compared to an estimate of ($0.025), with total revenue for the quarter at $93.2 million vs. an estimate of $83.26 million.
Market OpportunityExpanding leniolisib into the pediatric population addresses an unmet medical need and represents a substantial market opportunity.
Regulatory ApprovalThe FDA's sNDA approval for leniolisib as a treatment for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS) highlights a significant advancement for Pharming Group Nv.
Bears Say
Pharming Group News
PHAR FAQ
What was Pharming Group Nv’s price range in the past 12 months?
Pharming Group Nv lowest stock price was $7.31 and its highest was $17.08 in the past 12 months.
What is Pharming Group Nv’s market cap?
Pharming Group Nv’s market cap is $1.05B.
When is Pharming Group Nv’s upcoming earnings report date?
Pharming Group Nv’s upcoming earnings report date is Nov 06, 2025 which is in 29 days.
How were Pharming Group Nv’s earnings last quarter?
Pharming Group Nv released its earnings results on Jul 31, 2025. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of -$0.105 by $0.165.
Is Pharming Group Nv overvalued?
According to Wall Street analysts Pharming Group Nv’s price is currently Undervalued.
Does Pharming Group Nv pay dividends?
Pharming Group Nv does not currently pay dividends.
What is Pharming Group Nv’s EPS estimate?
Pharming Group Nv’s EPS estimate is <0.01.
How many shares outstanding does Pharming Group Nv have?
Pharming Group Nv has 68,514,760 shares outstanding.
What happened to Pharming Group Nv’s price movement after its last earnings report?
Pharming Group Nv reported an EPS of $0.06 in its last earnings report, beating expectations of -$0.105. Following the earnings report the stock price went up 10.109%.
Which hedge fund is a major shareholder of Pharming Group Nv?
Currently, no hedge funds are holding shares in PHAR
Pharming Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$39.00 (153.58% Upside)
$39.00 (153.58% Upside)
Blogger Sentiment
Bullish
PHAR Sentiment 70%
Sector Average 73%
Sector Average 73%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 7.2%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
91.30%
12-Months-Change
Fundamentals
Return on Equity
-3.40%
Trailing 12-Months
Asset Growth
7.29%
Trailing 12-Months
Company Description
Pharming Group Nv
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
PHAR Company Deck
PHAR Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong positive sentiment due to significant revenue growth, a turnaround in operating profits, and expansion of the pipeline. However, there are some concerns about inventory impacts on revenue and potential market disruptions.View all PHAR earnings summariesPHAR Stock 12 Month Forecast
Average Price Target
$39.00
▲(153.58% Upside)
Technical Analysis
Trevi Therapeutics
―
Oric Pharmaceuticals
―
Praxis Precision Medicines
―
ARS Pharmaceuticals
―
Prime Medicine, Inc.
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
0.08% Other Institutional Investors
99.92% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---